CYCN
Cyclerion Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Price History
Fundamentals
| Market Cap | $14.59M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.57 |
| EPS (TTM) | $-1.31 |
| Dividend Yield | - |
| Profit Margin | -264.73% |
| Revenue Growth | - |
| ROE | -67.77% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $8.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 68.2 |
| Beta | 1.77 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $8.48 |
| 52-Week Low | $1.03 |
| 50-Day Avg | $3.15 |
| 200-Day Avg | $2.18 |
| Avg Volume | 199.7K |
| Volume | 27.0K |
Performance Analysis
BULLISHCYCN shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:05 UTC
Back to Screener Export Report